Literature DB >> 7527427

Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1.

H Salomon1, A Belmonte, K Nguyen, Z Gu, M Gelfand, M A Wainberg.   

Abstract

We have shown that umbilical cord blood mononuclear cells (CBMC) are at least as sensitive as peripheral blood mononuclear cells (PBMC) for isolation of human immunodeficiency virus type 1 from the PBMC of infected individuals. Viral replication was more efficiently monitored by a p24 antigen capture assay than by a viral reverse transcriptase test, regardless of whether CBMC or PBMC were employed. We also found that CBMC and PBMC yielded similar results with regard to the susceptibility profiles of both wild-type and drug-resistant variants of human immunodeficiency virus type 1 for 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, and the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Finally, viruses isolated on CBMC could be routinely grown on PBMC and vice versa.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527427      PMCID: PMC263918          DOI: 10.1128/jcm.32.8.2000-2002.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.

Authors:  Q Gao; Z X Gu; M A Parniak; X G Li; M A Wainberg
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

2.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

3.  Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group.

Authors:  R Rooke; M Tremblay; H Soudeyns; L DeStephano; X J Yao; M Fanning; J S Montaner; M O'Shaughnessy; K Gelmon; C Tsoukas
Journal:  AIDS       Date:  1989-07       Impact factor: 4.177

4.  Detection of unintegrated human immunodeficiency virus type 1 DNA in persistently infected CD8+ cells.

Authors:  L Mercure; D Phaneuf; M A Wainberg
Journal:  J Gen Virol       Date:  1993-10       Impact factor: 3.891

5.  Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial.

Authors:  J S Montaner; J Singer; M T Schechter; J M Raboud; C Tsoukas; M O'Shaughnessy; J Ruedy; K Nagai; H Salomon; B Spira
Journal:  AIDS       Date:  1993-02       Impact factor: 4.177

6.  A molecular clone of HTLV-III with biological activity.

Authors:  A G Fisher; E Collalti; L Ratner; R C Gallo; F Wong-Staal
Journal:  Nature       Date:  1985 Jul 18-24       Impact factor: 49.962

7.  Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.

Authors:  Z Gu; Q Gao; X Li; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

8.  Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.

Authors:  Z Gu; Q Gao; H Fang; H Salomon; M A Parniak; E Goldberg; J Cameron; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.

Authors:  A J Japour; D L Mayers; V A Johnson; D R Kuritzkes; L A Beckett; J M Arduino; J Lane; R J Black; P S Reichelderfer; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

  9 in total
  14 in total

1.  Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.

Authors:  Michel Ntemgwa; Bluma G Brenner; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.

Authors:  Z Gu; M A Wainberg; N Nguyen-Ba; L L'Heureux; J M de Muys; T L Bowlin; R F Rando
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

3.  Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection.

Authors:  Bluma G Brenner; Jean-Pierre Routy; Marco Petrella; Daniela Moisi; Maureen Oliveira; Mervi Detorio; Bonnie Spira; Vidal Essabag; Brian Conway; Richard Lalonde; Rafick-Pierre Sekaly; Mark A Wainberg
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

4.  Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.

Authors:  Eugene L Asahchop; Maureen Oliveira; Mark A Wainberg; Bluma G Brenner; Daniela Moisi; Thomas d'Aquin Toni; Cecile L Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

5.  Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.

Authors:  Marco Petrella; Maureen Oliveira; Daniela Moisi; Mervi Detorio; Bluma G Brenner; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes.

Authors:  Irene Lisovsky; Susan M Schader; Jorge-Luis Martinez-Cajas; Maureen Oliveira; Daniela Moisi; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

7.  Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure.

Authors:  Gustavo H Kijak; Viviana Simon; Peter Balfe; Jeroen Vanderhoeven; Sandra E Pampuro; Carlos Zala; Claudia Ochoa; Pedro Cahn; Martin Markowitz; Horacio Salomon
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  Dual-reporter phenotypic assay for human immunodeficiency viruses.

Authors:  Keiko Kajiwara; Eiichi Kodama; Yasuko Sakagami; Takeshi Naito; Masao Matsuoka
Journal:  J Clin Microbiol       Date:  2007-12-19       Impact factor: 5.948

9.  Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.

Authors:  Michel Ntemgwa; Mark A Wainberg; Maureen Oliveira; Daniela Moisi; Richard Lalonde; Valeria Micheli; Bluma G Brenner
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

10.  Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.

Authors:  Yudong Quan; Bluma G Brenner; Maureen Oliveira; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.